Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Jounce Therapeutics, Inc. (JNCE : NSDQ)
 
 • Company Description   
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.

Number of Employees: 137

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.02 Daily Weekly Monthly
20 Day Moving Average: 341,834 shares
Shares Outstanding: 51.67 (millions)
Market Capitalization: $156.06 (millions)
Beta: 1.21
52 Week High: $9.81
52 Week Low: $2.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.94% -15.09%
12 Week -58.86% -51.72%
Year To Date -63.83% -54.94%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
780 MEMORIAL DRIVE
-
CAMBRIDGE,MA 02139
USA
ph: 857-259-3840
fax: -
mdeon@jouncetx.com http://www.jouncetx.com
 
 • General Corporate Information   
Officers
Richard Murray - President; Chief Executive Officer
Perry A. Karsen - Chairman
Kim C. Drapkin - Treasurer and Chief Financial Officer
Luis A. Diaz, Jr. - Director
Barbara Duncan - Director

Peer Information
Jounce Therapeutics, Inc. (GSAC)
Jounce Therapeutics, Inc. (CASI)
Jounce Therapeutics, Inc. (ALCD.)
Jounce Therapeutics, Inc. (OMNN)
Jounce Therapeutics, Inc. (CGPI.)
Jounce Therapeutics, Inc. (ISR)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 481116101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 51.67
Most Recent Split Date: (:1)
Beta: 1.21
Market Capitalization: $156.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.83
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -24.14%
vs. Previous Quarter: -22.03%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 1,548.34%
ROE
06/30/22 - -
03/31/22 - -43.16
12/31/21 - -35.19
ROA
06/30/22 - -
03/31/22 - -38.60
12/31/21 - -31.76
Current Ratio
06/30/22 - -
03/31/22 - 9.87
12/31/21 - 10.10
Quick Ratio
06/30/22 - -
03/31/22 - 9.87
12/31/21 - 10.10
Operating Margin
06/30/22 - -
03/31/22 - -
12/31/21 - -
Net Margin
06/30/22 - -
03/31/22 - -
12/31/21 - -
Pre-Tax Margin
06/30/22 - -
03/31/22 - -400.86
12/31/21 - -337.67
Book Value
06/30/22 - -
03/31/22 - 3.66
12/31/21 - 4.37
Inventory Turnover
06/30/22 - -
03/31/22 - -
12/31/21 - -
Debt-to-Equity
06/30/22 - -
03/31/22 - 0.00
12/31/21 - 0.00
Debt-to-Capital
06/30/22 - -
03/31/22 - 0.00
12/31/21 - 0.00
 

Powered by Zacks Investment Research ©